Javascript must be enabled to continue!
To assess the drug safety and efficacy of sofosbuvir plus velpatasvir in hepatitis C patients
View through CrossRef
Hepatitis is an inflammation of the liver. The condition can be self-limiting or can progress to fibrosis (scarring), cirrhosis or liver cancer. Hepatitis viruses are the most common cause of hepatitis in the world, but other infections, toxic substances (e.g. alcohol, certain drugs), and auto-immune diseases can also cause hepatitis. To assess the treatment efficacy of sofosbuvir and velpatasvir to chronic hepatitis C virus-infected patients and to assess the treatment efficacy among the various subgroups of the treated patients. The primary endpoint will be to assess sustained virologic response at 12 weeks (sofosbuvir + velpatasvir) after the end of therapy. The objective of the study is that hepatitis C virus is a rare viral disease occurring in the society with prevalence rate to be around 0.5% to 1.5%. So this study helps to assess the safety and efficacy of sofosbuvir and velpatasvir in hepatitis C virus-infected patients. This study is a prospective study. The study was carried in Gandhi Hospital, Secunderabad, Telangana, India, which is a multispecialty hospital with a bed capacity of 1200. The study is conducted in the Gastroenterology and Hepatology department (both inpatients and OP patients). The present study shows that sofosbuvir and velpatasvir provides a significant effect by decreasing HCV RNA levels, decreasing the duration of therapy and fewer adverse events compared to other existing therapies. Low incidence of side effects in the present study established the safety profile of the drug in 6 months period. In this study, most adverse events noticed were headache and fatigue. Sofosbuvir and velpatasvir yield the most favourable future health economic outcomes, compared with other currently available regimens across a broad spectrum of patients, including those with different treatments. Further elucidation of the side effects, a more extended period of sofosbuvir and velpatasvir and, more number of patients need to be studied.
Title: To assess the drug safety and efficacy of sofosbuvir plus velpatasvir in hepatitis C patients
Description:
Hepatitis is an inflammation of the liver.
The condition can be self-limiting or can progress to fibrosis (scarring), cirrhosis or liver cancer.
Hepatitis viruses are the most common cause of hepatitis in the world, but other infections, toxic substances (e.
g.
alcohol, certain drugs), and auto-immune diseases can also cause hepatitis.
To assess the treatment efficacy of sofosbuvir and velpatasvir to chronic hepatitis C virus-infected patients and to assess the treatment efficacy among the various subgroups of the treated patients.
The primary endpoint will be to assess sustained virologic response at 12 weeks (sofosbuvir + velpatasvir) after the end of therapy.
The objective of the study is that hepatitis C virus is a rare viral disease occurring in the society with prevalence rate to be around 0.
5% to 1.
5%.
So this study helps to assess the safety and efficacy of sofosbuvir and velpatasvir in hepatitis C virus-infected patients.
This study is a prospective study.
The study was carried in Gandhi Hospital, Secunderabad, Telangana, India, which is a multispecialty hospital with a bed capacity of 1200.
The study is conducted in the Gastroenterology and Hepatology department (both inpatients and OP patients).
The present study shows that sofosbuvir and velpatasvir provides a significant effect by decreasing HCV RNA levels, decreasing the duration of therapy and fewer adverse events compared to other existing therapies.
Low incidence of side effects in the present study established the safety profile of the drug in 6 months period.
In this study, most adverse events noticed were headache and fatigue.
Sofosbuvir and velpatasvir yield the most favourable future health economic outcomes, compared with other currently available regimens across a broad spectrum of patients, including those with different treatments.
Further elucidation of the side effects, a more extended period of sofosbuvir and velpatasvir and, more number of patients need to be studied.
Related Results
The Impact of IL28B Gene Polymorphisms on Drug Responses
The Impact of IL28B Gene Polymorphisms on Drug Responses
To achieve high therapeutic efficacy in the patient, information on pharmacokinetics, pharmacodynamics, and pharmacogenetics is required. With the development of science and techno...
IgM antibody to hepatitis C virus in acute and chronic hepatitis C
IgM antibody to hepatitis C virus in acute and chronic hepatitis C
To assess possible role of testing for IgM-specific antibody in the diagnosis and monitoring of patients with hepatitis C, we tested sera from 14 patients with acute and 97 patient...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Prevalence of Hepatitis C Virus Infection in Hemodialysis Patients: A Longitudinal Study Comparing the Results of RNA and Antibody Assays
Prevalence of Hepatitis C Virus Infection in Hemodialysis Patients: A Longitudinal Study Comparing the Results of RNA and Antibody Assays
We longitudinally studied 51 patients from two hemodialysis centers to determine the prevalence of hepatitis C virus infection in hemodialysis patients. Serum samples were tested f...
Efficacy of DAA-based Antiviral Therapies for HCV Patients with Chronic Kidney Disease: A Meta-analysis
Efficacy of DAA-based Antiviral Therapies for HCV Patients with Chronic Kidney Disease: A Meta-analysis
Context: HCV infection in patients with chronic kidney disease (CKD) is important to be treated because it's associated with increased healthcare costs, utilization and is pertaine...
P1333 Patients with Inflammatory Bowel Disease exhibit poor response to Hepatitis B vaccination but maintain protective Measles antibody titres
P1333 Patients with Inflammatory Bowel Disease exhibit poor response to Hepatitis B vaccination but maintain protective Measles antibody titres
Abstract
Background
Patients with inflammatory bowel disease (IBD) are prone to infections due to disease activity, malnu...
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND
As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial
COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA virus similar to the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is an approved d...

